earnings
confidence high
sentiment neutral
materiality 0.50
Integrated BioPharma Q4 net income $0.3M ($0.01/share); FY net income $112K vs loss $34K
INTEGRATED BIOPHARMA INC
- Revenue Q4 $12.7M (-2.3% YoY); FY $50.3M (-0.7% YoY).
- Operating income improved to $402K Q4 and $251K FY, from $79K and $120K prior.
- Net income Q4 $268K ($0.01 diluted) vs $40K ($0.00); FY net income $112K ($0.00) vs net loss $34K.
- Two largest customers accounted for 90% of FY2024 revenue (89% prior year).
- Co-CEOs cite focus on core businesses and new prospects to diversify customer base.